Physician profile
Scott E Carlson
NPI 1659373116
$347.71
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $72.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $44.98 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $30.97 | 2019 | |
| Lilly USA, LLC | $29.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.01 | 2019 | |
| Amgen INC. | $17.17 | 2019 | |
| Edw Pharma, INC. | $17.08 | 2019 | |
| Genzyme Corporation | $15.73 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.13 | 2019 | |
| Ucb, INC. | $14.77 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.